Idea or Concept – Page 21

Citizen Health Secures $14.5M in Seed Funding to Revolutionize Rare Disease Care with AI-Powered Data Platform

12 months ago talkbio0Tagged AI-Powered Data Platform, Chan, Citizen, Health, Health care facility, Initiative, Personalized, Rare Disease Care, Zuckerberg

Citizen Health, Rare Disease Care, AI-Powered Data Platform, Seed Funding, Chan Zuckerberg Initiative, Personalized Healthcare

Breakthrough in Heart Disease Treatment: Lilly’s Muvalaplin and Silence Therapeutics’ Zerlasiran Show Promising Results in Lowering Lipoprotein(a) Levels

12 months ago talkbio0Tagged Atherosclerosis, Cardiovascular system, Gene Silencing Therapy, Heart Disease, Interferes with, Lipoprotein(a ), Lp(a ), Muvalaplin, Risk, RNA, zerlasiran

Lipoprotein(a) (Lp(a)), Heart Disease, Muvalaplin, Zerlasiran, Cardiovascular Risk, Gene Silencing Therapy, RNA Interference, Atherosclerotic Cardiovascular Disease

Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events

12 months ago talkbio0Tagged Cardiovascular system, cholesterol, Eli, Eli Lilly, Lipoprotein(a ), Lp(a ), Muvalaplin, oral drug, Phase 2 Clinical Trials, Risk

Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction

23andMe Restructures, Cuts 40% of Workforce and Ends Therapeutics Division Amid Financial Struggles

12 months ago talkbio0Tagged financial struggles, Genetic testing for cancer risk, Transection (procedure)

23andMe, layoffs, therapeutics division, financial struggles, genetic testing, data security

European Commission Imposes €463 Million Fine on Teva for Anti-Competitive Practices in MS Drug Market

1 year ago talkbio0Tagged Commission, competition, Copaxone, Dominance, European (ethnic group), Market, Mississippi (geographic location), MS, tactics, Teva

Teva, European Commission, fine, MS drug, competition tactics, Copaxone, market dominance

Eli Lilly’s Stock Plummets Following Q3 Earnings Miss and Reduced Revenue Forecast

1 year ago talkbio0Tagged Diabetes, Drops - Drug Form, drug sales, earnings, Eli, Eli Lilly, Obesity, Weight-Loss Agents

Eli Lilly, Q3 earnings, revenue forecast, stock drop, diabetes drugs, weight-loss drugs, obesity drug sales

Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients

1 year ago talkbio0Tagged Alzheimer 's disease, ARIA-E, Cerebral Edema, Changing, dosing, Eli, Eli Lilly, Kisunla, Risk, Treatment Protocols

Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction

Iambic Therapeutics Enhances AI Suite with “Enchant” for Predictive Preclinical Drug Development

1 year ago talkbio0Tagged Artificial Intelligence, clinical success, Drug Discovery, Enchant, Iambic, preclinical predictive powers, Prediction

Iambic Therapeutics, AI, Enchant, preclinical predictive powers, drug discovery, clinical success prediction

Tyra Biosciences Unveils Early Data for FGFR3 Inhibitor, TYRA-300, in Challenge to J&J’s Balversa

1 year ago talkbio0Tagged Balversa, Carcinoma, Transitional Cell, concerns, Effectiveness, FGFR3 protein, human, Inhibitor, J&J, Malignant neoplasm of urinary bladder, Safety, Tyra Biosciences, TYRA-300

Tyra Biosciences, TYRA-300, Balversa, J&J, bladder cancer, urothelial carcinoma, FGFR3 inhibitor, safety concerns, efficacy data

CDC Recommends Pneumococcal Vaccination for Adults 50 Years and Older

1 year ago talkbio0Tagged Administration of vaccine product containing only Streptococcus pneumoniae antigen (procedure), Adult, Centers for Disease Control and Prevention (U.S.), older, pneumococcal disease prevention, Recommendation, respiratory season

Pneumococcal vaccination, CDC recommendations, adults 50 and older, pneumococcal disease prevention, winter respiratory season.